Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0149 | 0.3353 | 0.3353 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0213 | 0.4939 | 1 |
Echinococcus multilocularis | muscleblind protein 1 | 0.0149 | 0.3353 | 0.3353 |
Loa Loa (eye worm) | hypothetical protein | 0.0149 | 0.3353 | 0.3353 |
Onchocerca volvulus | 0.0088 | 0.1846 | 0.9087 | |
Loa Loa (eye worm) | TAR-binding protein | 0.0063 | 0.1238 | 0.1238 |
Echinococcus granulosus | intermediate filament protein | 0.0027 | 0.0343 | 0.0343 |
Loa Loa (eye worm) | intermediate filament protein | 0.0027 | 0.0343 | 0.0343 |
Brugia malayi | Trypsin family protein | 0.0094 | 0.1997 | 0.1969 |
Onchocerca volvulus | 0.0094 | 0.1997 | 1 | |
Brugia malayi | Muscleblind-like protein | 0.0149 | 0.3353 | 0.333 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0094 | 0.1997 | 0.3574 |
Echinococcus multilocularis | lamin dm0 | 0.0027 | 0.0343 | 0.0343 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0063 | 0.1238 | 0.1207 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.0343 | 0.0343 |
Loa Loa (eye worm) | RNA binding protein | 0.0063 | 0.1238 | 0.1238 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0036 | 0.0565 | 0.0479 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0036 | 0.0565 | 0.0565 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0027 | 0.0343 | 0.0309 |
Echinococcus granulosus | muscleblind protein | 0.0149 | 0.3353 | 0.3353 |
Schistosoma mansoni | hypothetical protein | 0.0036 | 0.0565 | 0.0479 |
Trichomonas vaginalis | serine threonine-protein kinase, putative | 0.0213 | 0.4939 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0036 | 0.0565 | 0.0565 |
Brugia malayi | TAR-binding protein | 0.0063 | 0.1238 | 0.1207 |
Brugia malayi | RNA binding protein | 0.0063 | 0.1238 | 0.1207 |
Echinococcus granulosus | lamin dm0 | 0.0027 | 0.0343 | 0.0343 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 0.1238 | 0.1933 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 0.1238 | 0.1933 |
Echinococcus multilocularis | lamin | 0.0027 | 0.0343 | 0.0343 |
Echinococcus multilocularis | dnaJ subfamily C 6 | 0.0061 | 0.1186 | 0.1186 |
Brugia malayi | hypothetical protein | 0.0036 | 0.0565 | 0.0531 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0214 | 0.4971 | 1 |
Loa Loa (eye worm) | DnaJ domain-containing protein | 0.0061 | 0.1186 | 0.1186 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0027 | 0.0343 | 0.0343 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 0.1238 | 0.1933 |
Echinococcus granulosus | lamin | 0.0027 | 0.0343 | 0.0343 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0063 | 0.1238 | 0.1238 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 0.1238 | 0.1933 |
Loa Loa (eye worm) | hypothetical protein | 0.0094 | 0.1997 | 0.1997 |
Echinococcus multilocularis | musashi | 0.0027 | 0.0343 | 0.0343 |
Loa Loa (eye worm) | hypothetical protein | 0.0094 | 0.1997 | 0.1997 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 0.1238 | 0.1933 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0014 | 0.0035 | 0.0035 |
Echinococcus granulosus | tar DNA binding protein | 0.0063 | 0.1238 | 0.1238 |
Schistosoma mansoni | hypothetical protein | 0.0061 | 0.1186 | 0.1822 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.0331 | 0.0331 |
Echinococcus multilocularis | tar DNA binding protein | 0.0063 | 0.1238 | 0.1238 |
Echinococcus multilocularis | muscleblind protein | 0.0149 | 0.3353 | 0.3353 |
Brugia malayi | intermediate filament protein | 0.0027 | 0.0343 | 0.0309 |
Echinococcus granulosus | dnaJ subfamily C 6 | 0.0061 | 0.1186 | 0.1186 |
Brugia malayi | DnaJ domain containing protein | 0.0061 | 0.1186 | 0.1155 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0094 | 0.1997 | 0.3574 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -5.27 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5.13 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.913 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.817 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.767 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.764 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.745 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.72 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.